Výsledky vyhledávání

P781 Treatment outcome of tofacitinib dose reduction to 5 mg BID vs remaining on 10 mg BID in patients with Ulcerative Colitis who were in stable remission on 10 mg BID: Updated 30-month data from the double-blind, randomised RIVETING study

Autor: D T Rubin, J Panés, J Torres, T Kobayashi, C Su, N Lawendy, I Modesto, M Segovia, S Gardiner, W Wang, S Vermeire

Publikováno v: Journal of Crohn's and Colitis. 17:i914-i916

Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. The long-term, Phase 3b/4 RIVETING study (NCT03281304) assessed the efficacy and safety of tofacitinib dose reduction from tofacitinib 10

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b116b6029de37a2413af89f269c65b4a
https://doi.org/10.1093/ecco-jcc/jjac190.0911

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P477 Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open

Autor: J R Allegretti, K B Gecse, M V Chiorean, M Argollo, X Guo, N Lawendy, C Su, R Mundayat, J Paulissen, L Salese, P M Irving

Publikováno v: Journal of Crohn's and Colitis. 16:i446-i447

Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Patients may require retreatment following treatment interruption for reasons such as adverse events or pregnancy.1 In the tofacitinib UC cl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d585f054b67028c0ccb1c2a32b119b2d
https://doi.org/10.1093/ecco-jcc/jjab232.604

Zobrazit plný text záznamu

OP38 Tofacitinib for the treatment of Ulcerative Colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trials

Autor: W J Sandborn, G R D’Haens, B E Sands, R Panaccione, S C Ng, N Lawendy, N Kulisek, X Guo, R Mundayat, C Su, J Panés

Publikováno v: Journal of Crohn's and Colitis. 16:i044-i045

Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Efficacy and safety of tofacitinib were evaluated in randomised, placebo-controlled Phase (P)2 (NCT00787202) and P3 (NCT01465763; NCT0145895

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a3777955c4cd5f08ae71987170913c1
https://doi.org/10.1093/ecco-jcc/jjab232.037

Zobrazit plný text záznamu

P607 Efficacy and safety of tofacitinib in Ulcerative Colitis patients with extraintestinal manifestations in OCTAVE Open

Autor: D T Rubin, S R Vavricka, A Armuzzi, M C Dubinsky, A I Sharara, I Modesto, M Fellmann, G Liguori, N Lawendy, M J Cadatal, G R Lichtenstein

Publikováno v: Journal of Crohn's and Colitis. 16:i538-i539

Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Data from OCTAVE Induction 1&2 and OCTAVE Sustain demonstrated that a history of extraintestinal manifestations (EIMs) was shown not to infl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8198513af5e662a6e854e4aa23e396b
https://doi.org/10.1093/ecco-jcc/jjab232.733

Zobrazit plný text záznamu

P378 Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to, 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib, 5 mg BID maintenance therapy: Results from OCTAVE Open

Autor: J R Allegretti, K B Gecse, M V Chiorean, M Argollo, X Guo, N Lawendy, C Su, R Mundayat, J Paulissen, L Salese, P M Irving

Publikováno v: Journal of Crohn's and Colitis. 16:i380-i381

Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). In the tofacitinib UC clinical programme, patients who responded to tofacitinib, 10 mg BID during induction, and experienced treatment failu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::994846b4db57be50333e24d7908e58ee
https://doi.org/10.1093/ecco-jcc/jjab232.505

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme

Autor: B E Sands, P R Taub, B G Feagan, A Armuzzi, A O Damião, N Lawendy, G Solano, K Kwok, J Woolcott, L Salese, C Su

Publikováno v: Journal of Crohn's and Colitis. 14:S557-S558

Background Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). In the tofacitinib UC clinical programme, the majority of patients did not have cardiovascular (CV) risk factors at baseline (BL), and incre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c1d81846b91b1b1755b865df58b1c671
https://doi.org/10.1093/ecco-jcc/jjz203.812

Zobrazit plný text záznamu

A202 TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 5.4 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

Autor: W J Sandborn, J Panés, R Panaccione, G D’Haens, B E Sands, C Su, M Moscariello, T V Jones, R D Pedersen, G S Friedman, N Lawendy, G Chan

BACKGROUND: Tofacitinib is an oral, small molecule JAK inhibitor approved in several countries for the treatment of ulcerative colitis (UC). Efficacy and safety of tofacitinib as UC induction and maintenance therapy were evaluated in Phase (P)2(1) an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::450e7722e444c2b880e8fe6093d6e45a
https://europepmc.org/articles/PMC6512642/

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání